Cargando…
Potential of heparin and nafamostat combination therapy for COVID‐19
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906352/ https://www.ncbi.nlm.nih.gov/pubmed/32302456 http://dx.doi.org/10.1111/jth.14858 |
| _version_ | 1784883975160856576 |
|---|---|
| author | Asakura, Hidesaku Ogawa, Haruhiko |
| author_facet | Asakura, Hidesaku Ogawa, Haruhiko |
| author_sort | Asakura, Hidesaku |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9906352 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99063522023-02-08 Potential of heparin and nafamostat combination therapy for COVID‐19 Asakura, Hidesaku Ogawa, Haruhiko J Thromb Haemost Letter to the Editor International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. 2020-06 2022-12-21 /pmc/articles/PMC9906352/ /pubmed/32302456 http://dx.doi.org/10.1111/jth.14858 Text en Copyright © 2020 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Asakura, Hidesaku Ogawa, Haruhiko Potential of heparin and nafamostat combination therapy for COVID‐19 |
| title | Potential of heparin and nafamostat combination therapy for COVID‐19 |
| title_full | Potential of heparin and nafamostat combination therapy for COVID‐19 |
| title_fullStr | Potential of heparin and nafamostat combination therapy for COVID‐19 |
| title_full_unstemmed | Potential of heparin and nafamostat combination therapy for COVID‐19 |
| title_short | Potential of heparin and nafamostat combination therapy for COVID‐19 |
| title_sort | potential of heparin and nafamostat combination therapy for covid‐19 |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906352/ https://www.ncbi.nlm.nih.gov/pubmed/32302456 http://dx.doi.org/10.1111/jth.14858 |
| work_keys_str_mv | AT asakurahidesaku potentialofheparinandnafamostatcombinationtherapyforcovid19 AT ogawaharuhiko potentialofheparinandnafamostatcombinationtherapyforcovid19 |